➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Mallinckrodt
McKesson
Merck
Moodys

Last Updated: September 24, 2021

DrugPatentWatch Database Preview

Rilonacept - Biologic Drug Details


Email this page to a colleague

« Back to Dashboard

Summary for rilonacept
Tradenames:1
Patents:29
Applicants:1
BLAs:1
Suppliers: see list1
Recent Clinical Trials: See clinical trials for rilonacept
Recent Clinical Trials for rilonacept

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Kiniksa Pharmaceuticals, Ltd.Phase 3
Kiniksa Pharmaceuticals, Ltd.Phase 2
Karoline KrausePhase 2

See all rilonacept clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for rilonacept Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for rilonacept Derived from Company Disclosures

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Regeneron Pharmaceuticals ARCALYST rilonacept VIAL; SINGLE-USE 125249 001 2008-02-27 ⤷  Free Forever Trial Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) 2013-10-20 RX Orphan company
Regeneron Pharmaceuticals ARCALYST rilonacept VIAL; SINGLE-USE 125249 001 2008-02-27 ⤷  Free Forever Trial Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) 2018-09-25 RX Orphan company
Regeneron Pharmaceuticals ARCALYST rilonacept VIAL; SINGLE-USE 125249 001 2008-02-27 ⤷  Free Forever Trial Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) 2018-09-25 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

3) Low Certainty: US Patents for rilonacept Derived from Patent Text Search

These patents were identified by searching patent claims

International Patents for rilonacept

Country Patent Number Estimated Expiration
Slovenia 2041177 ⤷  Free Forever Trial
Russian Federation 2433138 ⤷  Free Forever Trial
European Patent Office 3294301 ⤷  Free Forever Trial
Russian Federation 2008152443 ⤷  Free Forever Trial
Denmark 1572967 ⤷  Free Forever Trial
Japan 2014511427 ⤷  Free Forever Trial
Slovenia 2374818 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration

Supplementary Protection Certificates for rilonacept

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
5007-2010 Slovakia ⤷  Free Forever Trial PRODUCT NAME: RILONACEPT; REGISTRATION NO/DATE: EU/1/09/582/001 20091023
0100004 00030 Estonia ⤷  Free Forever Trial PRODUCT NAME: ARCALYST-RILONACEPT; REG NO/DATE: C(2009)8377 23.10.2009
17C/054 Belgium ⤷  Free Forever Trial PRODUCT NAME: KEVZARA - SARILUMAB; AUTHORISATION NUMBER AND DATE: EU/1/17/1196 20170627
2017 00061 Denmark ⤷  Free Forever Trial PRODUCT NAME: SARILUMAB; REG. NO/DATE: EU/1/17/1196/001-8 20170627
00448 Netherlands ⤷  Free Forever Trial PRODUCT NAME: RILONACEPT; REGISTRATION NO/DATE: EU/1/09/582/001 20091023
2010 00016 Denmark ⤷  Free Forever Trial PRODUCT NAME: RILONACEPT
0911 Netherlands ⤷  Free Forever Trial PRODUCT NAME: SARILUMAB; REGISTRATION NO/DATE: EU/1/17/1196 20170627
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
Harvard Business School
McKesson
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.